Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, homologous pleckstrin-homology (PH)-domain
leucine-rich-repeat protein
phosphatases (PHLPP2) has been reported as a tumor suppressor in
colon cancer
. This study aimed to unravel the possible involvement of long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) regulating PHLPP2 in
colon cancer
. Expressions of candidate lncRNAs and miRNAs were verified by the RT-qPCR and Western blot analyses in
colon cancer
. The roles of candidate genes in
colon cancer
were investigated in HT-29 cells
in vitro
and in mouse tumor xenograft model
in vivo
. PHLPP2, a target of miR-141 and miR-424, was downregulated in
colon cancer
. PHLPP2 upregulation and miR-141 and miR-424 downregulation suppressed the
colon cancer
cell proliferation, migration, invasion, and epithelial-mesenchymal transition, and promote cell apoptosis, which also resulted in suppression of tumor metastasis and formation. Furthermore, LINC00402, LINC00461, and SFTA1P were identified as the targets of miR-141 and miR-424 and acted as competitive endogenous RNAs (ceRNAs) of PHLPP2. The upregulation of LINC00402, LINC00461, and SFTA1P was verified to enhance the suppressive effects of PHLPP2 in the pathogenesis of
colon cancer
. Conjointly, our results demonstrated the suppressive effects of PHLPP2 in
colon cancer
and proved that LINC00402, LINC00461, and SFTA1P acted as ceRNAs of PHLPP2 by competitive binding to miR-141 and miR-424.
...
PMID:PHLPP2 is regulated by competing endogenous RNA network in pathogenesis of colon cancer. 3263 26